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Background
Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, 
can overcome immune resistance. We assessed the antitumor activity and safety of 
BMS-936558, an antibody that specifically blocks PD-1.
Methods
We enrolled patients with advanced melanoma, non–small-cell lung cancer, castration-
resistant prostate cancer, or renal-cell or colorectal cancer to receive anti–PD-1 anti-
body at a dose of 0.1 to 10.0 mg per kilogram of body weight every 2 weeks. Response 
was assessed after each 8-week treatment cycle. Patients received up to 12 cycles 
until disease progression or a complete response occurred.
Results
A total of 296 patients received treatment through February 24, 2012. Grade 3 or 4 drug-
related adverse events occurred in 14% of patients; there were three deaths from 
pulmonary toxicity. No maximum tolerated dose was defined. Adverse events con-
sistent with immune-related causes were observed. Among 236 patients in whom 
response could be evaluated, objective responses (complete or partial responses) were 
observed in those with non–small-cell lung cancer, melanoma, or renal-cell cancer. 
Cumulative response rates (all doses) were 18% among patients with non–small-cell 
lung cancer (14 of 76 patients), 28% among patients with melanoma (26 of 94 patients), 
and 27% among patients with renal-cell cancer (9 of 33 patients). Responses were 
durable; 20 of 31 responses lasted 1 year or more in patients with 1 year or more of 
follow-up. To assess the role of intratumoral PD-1 ligand (PD-L1) expression in the 
modulation of the PD-1–PD-L1 pathway, immunohistochemical analysis was performed 
on pretreatment tumor specimens obtained from 42 patients. Of 17 patients with 
PD-L1–negative tumors, none had an objective response; 9 of 25 patients (36%) with 
PD-L1–positive tumors had an objective response (P = 0.006).
Conclusions
Anti–PD-1 antibody produced objective responses in approximately one in four to one 
in five patients with non–small-cell lung cancer, melanoma, or renal-cell cancer; the 
adverse-event profile does not appear to preclude its use. Preliminary data suggest a 
relationship between PD-L1 expression on tumor cells and objective response. (Fund-
ed by Bristol-Myers Squibb and others; ClinicalTrials.gov number, NCT00730639.)
The New England Journal of Medicine 
Downloaded from nejm.org at MUSC Library on January 21, 2015. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 366;26 nejm.org june 28, 20122444
Human cancers harbor numerous genetic and epigenetic alterations, gen-erating neoantigens that are potentially 
recognizable by the immune system.1 Although an 
endogenous immune response to cancer is ob-
served in preclinical models and patients, this 
response is ineffective, because tumors develop 
multiple resistance mechanisms, including local 
immune suppression, induction of tolerance, and 
systemic dysfunction in T-cell signaling.2-5 More-
over, tumors may exploit several distinct pathways 
to actively evade immune destruction, including en-
dogenous “immune checkpoints” that normally 
terminate immune responses after antigen activa-
tion. These observations have resulted in intensive 
efforts to develop immunotherapeutic approaches 
for cancer, including immune-checkpoint-pathway 
inhibitors such as anti–CTLA-4 antibody (ipilimu-
mab) for the treatment of patients with advanced 
melanoma.6-8
Programmed death 1 (PD-1) is a key immune-
checkpoint receptor expressed by activated T cells, 
and it mediates immunosuppression. PD-1 func-
tions primarily in peripheral tissues, where T cells 
may encounter the immunosuppressive PD-1 li-
gands PD-L1 (B7-H1) and PD-L2 (B7-DC), which 
are expressed by tumor cells, stromal cells, or 
both.9-12 Inhibition of the interaction between PD-1 
and PD-L1 can enhance T-cell responses in vitro 
and mediate preclinical antitumor activity.11,13 In 
a dose-escalation study, the anti–PD-1 monoclonal 
antibody BMS-936558 (also known as MDX-1106 
and ONO-4538) was administered as a single dose 
in 39 patients with advanced solid tumors.14 A 
favorable safety profile and preliminary evidence 
of clinical activity were shown in this pilot study, 
establishing the basis for the current multiple-
dose trial involving patients with diverse cancers. 




This study was sponsored by Bristol-Myers Squibb, 
which provided the study drug and worked joint-
ly with the senior academic authors to design, 
collect, analyze, and interpret the study results. 
All the authors signed a confidentiality agree-
ment with the sponsor. The protocol, including a 
detailed statistical analysis plan, is available with 
the full text of this article at NEJM.org. All drafts 
of the manuscript were prepared by the authors 
with editorial assistance from a professional 
medical writer paid by the sponsor. All the au-
thors vouch for the accuracy and completeness of 
the reported data and for the fidelity of this re-
port to the trial protocol, and all the authors 
made the decision to submit the manuscript for 
publication.
This phase 1 study assessed the safety, anti-
tumor activity, and pharmacokinetics of BMS-
936558, a fully human IgG4-blocking monoclo-
nal antibody directed against PD-1, in patients 
with selected advanced solid tumors. All patients 
(or their legal representatives) gave written in-
formed consent before enrollment. The antibody 
was administered as an intravenous infusion 
every 2 weeks of each 8-week treatment cycle. 
Response was assessed after each treatment cy-
cle. Patients received treatment for up to 2 years 
(12 cycles), unless they had a complete response, 
unacceptable adverse effects, or progressive dis-
ease or they withdrew consent. In clinically sta-
ble patients, study treatment could be continued 
beyond apparent initial disease progression until 
progression was confirmed, as outlined by pro-
posed immune-response criteria.15 Patients with 
stable disease or an ongoing objective response 
(complete or partial response) at the end of 
treatment were followed for up to 1 year and 
were offered retreatment for 1 additional year in 
the event of disease progression.
Safety evaluations (clinical examination and 
laboratory assessments) were conducted for all 
treated patients at baseline and regular intervals. 
The severity of adverse events was graded ac-
cording to the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events, 
version 3.0.16
Dose Escalation
Patients with advanced melanoma, non–small-
cell lung cancer, renal-cell cancer, castration- 
resistant prostate cancer, or colorectal cancer were 
enrolled. Cohorts of three to six patients per 
dose level were enrolled sequentially at doses of 
1.0, 3.0, or 10.0 mg per kilogram of body weight. 
Dose escalation proceeded when a minimum of 
three patients had completed the safety-evalua-
tion period (56 days) at a given dose level, with 
dose-limiting toxicity in less than one third of 
patients. Intrapatient dose escalation was not 
permitted.
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Cohort Expansion
A maximum tolerated dose was not reached. Ini-
tially, five expansion cohorts of approximately 16 
patients each were enrolled at doses of 10.0 mg 
per kilogram for melanoma, non–small-cell lung 
cancer, renal-cell cancer, castration-resistant pros-
tate cancer, and colorectal cancer. On the basis of 
initial signals of activity, additional expansion 
cohorts of approximately 16 patients each were 
enrolled for melanoma (at a dose of 1.0 or 3.0 mg 
per kilogram, followed by cohorts randomly as-
signed to 0.1, 0.3, or 1.0 mg per kilogram), lung 
cancer (patients with the squamous or nonsqua-
mous subtype, randomly assigned to a dose of 
1.0, 3.0, or 10.0 mg per kilogram), and renal-cell 
cancer (at a dose of 1.0 mg per kilogram).
Patients
Eligible patients had documented advanced solid 
tumors; an age of 18 years or older; a life expec-
tancy of 12 weeks or more; an Eastern Coopera-
tive Oncology Group performance status of 0, 1, 
or 2 (on a scale from 0 to 5, with 0 indicating that 
the patient is asymptomatic, 1 that the patient is 
restricted in strenuous activity, and 2 that the 
patient is ambulatory but unable to work)17; mea-
surable disease according to Response Evaluation 
Criteria in Solid Tumors (RECIST), version 1.0,18 
with modification (see Methods S1 in the Supple-
mentary Appendix, available at NEJM.org; and the 
protocol); adequate hematologic, hepatic, and re-
nal function; and a history of one to five systemic 
treatment regimens. Patients with radiographically 
stable treated brain metastases were enrolled. Pa-
tients with a history of chronic autoimmune dis-
ease, prior therapy with antibodies that modulate 
T-cell function (e.g., anti–CTLA-4, anti–PD-1, and 
anti–PD-L1), conditions requiring immunosup-
pressive medications, or chronic infection (e.g., hu-
man immunodeficiency virus infection and hepa-
titis B or C) were excluded.
Immunohistochemical Analysis for PD-L1
Immunohistochemical analysis for PD-L1 was per-
formed on archival or newly obtained pretreat-
ment formalin-fixed, paraffin-embedded tumor 
specimens with the use of the murine antihuman 
PD-L1 monoclonal antibody 5H1.11,19 The per-
centage of tumor cells exhibiting cell-surface 
staining for PD-L1 was scored by two indepen-
dent pathologists who were unaware of outcomes. 
PD-L1 positivity was defined per specimen by a 
5% expression threshold19,20; patients with mul-
tiple specimens were considered PD-L1–positive 
if any specimen met this criterion.
Pharmacokinetics and Pharmacodynamics
For pharmacokinetic analysis, serum concentra-
tions of anti–PD-1 antibody were quantified with 
the use of an enzyme-linked immunosorbent as-
say. For pharmacodynamic analysis, peripheral-
blood mononuclear cells (PBMCs) were isolated 
from patients at baseline and after the first treat-
ment cycle to estimate PD-1–receptor occupancy 
by the antibody on circulating CD3+ T cells by 
means of flow cytometry.14
Statistical Analysis
Data on all 296 patients treated as of the date of 
analysis for this report (February 24, 2012) were 
used for summaries of baseline characteristics 
and adverse events. Pharmacokinetic and molec-
ular-marker analyses included treated patients 
with available data as of February 24, 2012. The 
efficacy analysis included the 236 patients who 
could be evaluated for a response and who began 
treatment by July 1, 2011. Adverse events were cod-
ed with the use of the Medical Dictionary for Reg-
ulatory Activities (MedDRA), version 14.1. Adverse 
events of special interest, with a potential immune-
related cause, were identified with the use of a 
predefined list of MedDRA terms. The best re-
sponses in individual patients were derived from 
investigator-reported data per modified RECIST, 
version 1.0. Objective responses were confirmed 
by at least one sequential tumor assessment, and 
objective response rates were calculated as [(com-
plete responses + partial responses) ÷ number of 
patients] × 100. Fisher’s exact test was used to as-




A total of 296 patients with advanced solid tu-
mors, including melanoma (104 patients), non–
small-cell lung cancer (122), renal-cell cancer 
(34), castration-resistant prostate cancer (17), and 
colorectal cancer (19), began treatment with anti–
PD-1 antibody between October 2008 and Febru-
ary 24, 2012. The majority of patients were heav-
ily pretreated; 47% had received at least three 
prior regimens (Table S1-A in the Supplementary 
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Appendix). Notable prior therapies included im-
munotherapy and BRAF inhibitors in patients with 
melanoma (64% and 8% of patients, respectively); 
platinum-based chemotherapy and tyrosine kinase 
inhibitors in patients with lung cancer (94% and 
34%, respectively); and nephrectomy, immunother-
apy, and antiangiogenic therapy in patients with 
renal-cell cancer (94%, 59%, and 74%, respective-
ly) (Tables S1-B, S1-C, and S1-D in the Supplemen-
tary Appendix). Baseline characteristics of the to-
tal treated population (296 patients) were similar 
to those of the efficacy population (236 patients).
Safety
A maximum tolerated dose was not defined at 
the doses tested in this study. A relative dose in-
tensity (the proportion of administered doses 
relative to planned doses) of 90% or more was 
achieved in 86% of patients (Table S2-A in the 
Supplementary Appendix). Fifteen of 296 patients 
(5%) discontinued treatment owing to treatment-
related adverse events (Tables S2-B and S3-A in 
the Supplementary Appendix). As of the date of 
analysis, 62 patients (21%) had died; disease pro-
gression was the most common cause of death 
(Table S2-C in the Supplementary Appendix).
The most common adverse events, regardless 
of causality, were fatigue, decreased appetite, 
diarrhea, nausea, cough, dyspnea, constipation, 
vomiting, rash, pyrexia, and headache (Table S3-A 
in the Supplementary Appendix). Common treat-
ment-related adverse events included fatigue, 
rash, diarrhea, pruritus, decreased appetite, and 
nausea (Tables S3-A and S3-B in the Supplemen-
tary Appendix). Grade 3 or 4 treatment-related 
adverse events were observed in 41 of 296 pa-
tients (14%). Drug-related serious adverse events 
(as defined in Table S4 in the Supplementary 
Appendix) occurred in 32 of 296 patients (11%). 
The spectrum, frequency, and severity of treatment-
related adverse events were generally similar 
across the dose levels tested. Drug-related adverse 
events of special interest (e.g., those with potential 
immune-related causes) included pneumonitis, 
vitiligo, colitis, hepatitis, hypophysitis, and thy-
roiditis (Table 1 and Fig. 1C).
Hepatic or gastrointestinal adverse events were 
managed with treatment interruption and, as nec-
essary, with the administration of glucocorticoids. 
These events (e.g., diarrhea in 33 patients, includ-
ing three grade 3 or 4 events and elevated alanine 
aminotransferase levels in 11 patients, including 
two grade 3 or 4 events) were reversible in all cases. 
Endocrine disorders were managed with replace-
ment therapy. At the discretion of the treating 
physician, treatment with anti–PD-1 antibody was 
reinitiated once the adverse event had been suc-
cessfully managed. Drug-related pneumonitis oc-
curred in 9 of the 296 patients (3%). Grade 3 or 
4 pneumonitis developed in 3 patients (1%). No 
clear relationship between the occurrence of pneu-
monitis and tumor type, dose level, or the number 
of doses received was noted. Early-grade pneumo-
nitis in 6 patients was reversible with treatment 
discontinuation, glucocorticoid administration, or 
both. In 3 patients with pneumonitis, infliximab, 
mycophenolate, or both were used for additional 
immunosuppression; however, given the small 
number of patients and variable outcomes, the 
effectiveness of such treatment was unclear. There 
were three drug-related deaths (1%) due to pneu-
monitis (two in patients with non–small-cell lung 
cancer and one in a patient with colorectal cancer).
Clinical Activity
Antitumor activity was observed at all doses test-
ed. Objective responses were observed in a sub-
stantial proportion of patients with non–small-
cell lung cancer, melanoma, or renal-cell cancer 
(Table 2 and Fig. 1) and in various sites of metas-
tasis, including the liver, lung, lymph nodes, and 
bone. At the time of data analysis, two patients 
with lung cancer who received 10 mg per kilo-
gram had unconfirmed responses, and eight ad-
ditional patients (with melanoma, lung cancer, 
or renal-cell cancer) had a persistent reduction in 
baseline target lesions in the presence of new le-
sions (a finding consistent with an immune- 
related response pattern15). None of these patients 
were categorized as having had a response for 
the purpose of calculating objective-response 
rates. Objective responses, prolonged disease 
stabilization, or both were observed in patients 
who had received a variety of prior therapies. No 
objective responses were observed in patients 
with colorectal or prostate cancer.
In patients with lung cancer, 14 objective re-
sponses were observed at doses of 1.0, 3.0, or 
10.0 mg per kilogram, with response rates of 6%, 
32%, and 18%, respectively. Objective responses 
were observed across non–small-cell histologic 
types: in 6 of 18 patients (33%) with squamous 
tumors, 7 of 56 (12%) with nonsquamous tu-
mors, and 1 of 2 with tumors of unknown type. 
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All 14 patients with objective responses started 
treatment 24 weeks or more before data analysis, 
and of these, 8 had a response that lasted 24 
weeks or more (Table 2). Five of 14 patients with 
objective responses started treatment 1 year or 
more before data analysis, and of these, 2 had 
a response that lasted 1 year or more. Stable 
disease lasting 24 weeks or more was observed 
in 5 patients (7%) with lung cancer, all of whom 
had nonsquamous tumors.
In patients with melanoma, 26 objective re-
sponses were observed at doses ranging from 
0.1 to 10.0 mg per kilogram, with response rates 
ranging from 19 to 41% per dose level. At a dose 
of 3.0 mg per kilogram, objective responses were 
noted in 7 of 17 patients (41%). Of 26 patients 
with melanoma who had an objective response, 
18 started treatment 1 year or more before Feb-
ruary 24, 2012, and of these, 13 had a response 
that lasted 1 year or more. The remaining 8 pa-
tients with objective responses received study 
medication for less than 1 year, and 6 had re-
sponses ranging from 1.9 to 5.6 months. Stable 
disease lasting 24 weeks or more was observed 
in 6 patients (6%).
Among patients with renal-cell cancer, objec-
tive responses occurred in 4 of 17 patients (24%) 
treated with a dose of 1.0 mg per kilogram and 
5 of 16 (31%) treated with 10.0 mg per kilogram. 
Of 8 patients with objective responses who start-
ed treatment 1 year or more before data analysis, 
5 had a response that lasted 1 year or more. 
Stable disease lasting 24 weeks or more was 
observed in an additional 9 patients (27%).
Pharmacokinetics and Pharmacodynamics
The median time to the peak concentration of anti–
PD-1 antibody was 1 to 4 hours after the start of 
infusion. The pharmacokinetics of the antibody 
were linear, with a dose-proportional increase in 
the peak concentration and area under the curve 
calculated from day 1 to day 14 in the dose range 
of 0.1 to 10.0 mg per kilogram (35 patients). The 
pharmacodynamics of anti–PD-1 antibody were 
assessed according to PD-1–receptor occupancy 
on circulating CD3+ T cells. In PBMCs from 65 
patients with melanoma who were treated with 
one cycle of anti–PD-1 antibody at a dose of 0.1 to 
10.0 mg per kilogram every 2 weeks, the median 
PD-1–receptor occupancy by anti–PD-1 antibody 
was 64 to 70% according to dose level (Fig. 2A).
PD-L1 Expression in Tumors
Sixty-one pretreatment tumor specimens from 
42 patients (18 with melanoma, 10 with non–
small-cell lung cancer, 7 with colorectal cancer, 
5 with renal-cell cancer, and 2 with prostate can-
cer) (Table S5 in the Supplementary Appendix) 
were analyzed for PD-L1 expression on the sur-
face of tumor cells (Fig. 2B). Biopsy specimens 
from 25 of the 42 patients were positive for PD-
L1 expression by immunohistochemical analysis. 
Of these 25 patients, 9 (36%) had an objective 
Figure 1 (facing page). Activity of Anti–Programmed 
Death 1 (PD-1) Antibody in Patients with Treatment- 
Refractory Melanoma, Non–Small-Cell Lung Cancer,  
or Renal-Cell Cancer.
In Panel A, a representative plot shows changes from 
baseline in the tumor burden, measured as the sum of 
the longest diameters of target lesions, in 27 patients 
with melanoma who received anti–PD-1 antibody at  
a dose of 1.0 mg per kilogram of body weight every  
2 weeks. In the majority of patients who had an objec-
tive response, responses were durable and evident by 
the end of cycle 2 (16 weeks) of treatment. The vertical 
dashed line marks the 24-week time point at which the 
progression-free survival rate was calculated, and the 
horizontal dashed line marks the threshold for objective 
response (partial tumor regression) according to modi-
fied Response Evaluation Criteria in Solid Tumors. Tumor 
regression followed conventional as well as immune- 
related patterns of response, such as prolonged reduc-
tion in tumor burden in the presence of new lesions.15,21 
Panel B shows partial regression of metastatic renal-
cell cancer in a 57-year-old patient who received anti–
PD-1 antibody at a dose of 1.0 mg per kilogram. This 
patient had previously undergone radical surgery, and 
progressive disease had developed after treatment with 
sunitinib, temsirolimus, sorafenib, and pazopanib. The 
arrowheads show regression of recurrent tumor in the 
operative field. Panel C shows a complete response in 
a 62-year-old patient with metastatic melanoma who 
received anti–PD-1 antibody at a dose of 3.0 mg per kilo-
gram. Pretreatment computed tomographic scanning (i) 
revealed inguinal-lymph-node metastasis (arrowhead), 
which regressed completely after 13 months of treat-
ment (ii). Numerous metastases in the subcutaneous 
tissue and retroperitoneum also regressed completely 
(not shown). Vitiligo, which developed after 6 months 
of treatment, is evident in photographs taken at 9 months 
under visible light (iii) and ultraviolet light (iv). Skin- 
biopsy specimens with immunohistochemical staining 
for micro-ophthalmia–associated transcription factor 
show that melanocytes (arrows) are abundant at the 
epidermal–dermal junction in normal skin (v), scarce 
in skin partially affected by vitiligo (vi), and absent in 
skin fully affected by vitiligo (vii). Panel D shows a par-
tial response in a patient with metastatic non–small-
cell lung cancer (nonsquamous histologic type) who 
received anti–PD-1 antibody at a dose of 10.0 mg per 
kilogram. The arrowheads show initial progression in 
pulmonary lesions, followed by regression (an immune-
related pattern of response).
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response. None of the 17 patients with PD-L1–
negative tumors had an objective response. This 
analysis is based on optional biopsies in a non-
random subset of the population, and testing of 
a statistical hypothesis was not prespecified. 
These preliminary results must therefore be in-
terpreted with caution.
Discussion
Our data show that approximately one in four to 
one in five patients treated with anti–PD-1 anti-
body had objective responses with durability; these 
occurred in heavily pretreated patients with diverse 
tumor types. PD-1 blockade extends the spectrum 
of clinical activity by immunotherapy beyond im-
munogenic tumor types, such as melanoma and 
renal-cell cancer, to treatment-refractory, meta-
static non–small-cell lung cancer, a tumor type 
that is generally not considered to be responsive 
to immunotherapy. The level of activity seen with 
anti–PD-1 antibody in patients with lung cancer 
who had received substantial amounts of prior 
therapy (55% with at least three lines of previous 
therapy) (Table S1-B in the Supplementary Ap-
pendix) and across histologic types is of interest, 
particularly in the patients with squamous tu-
mors.22,23 These unexpected findings underscore 
Table 2. Clinical Activity of Anti–PD-1 Antibody in the Efficacy Population.*






Rate‡ Duration of Response§ Stable Disease ≥24 wk
Progression-free 
Survival Rate  
at 24 wk¶
no. of patients/ 
total no. of  
patients % (95% CI) mo
no. of patients/ 
total no. of  
patients % (95% CI) % (95% CI)
Melanoma
0.1 mg/kg 4/14 29 (8–58) 7.5+, 5.6+, 5.6, 5.6 1/14 7 (0.2–34) 40 (13–66)
0.3 mg/kg 3/16 19 (4–46) 3.8+, 2.1+, 1.9+ 1/16 6 (0.2–30) 31 (9–54)
1.0 mg/kg 8/27 30 (14–50) 24.9+, 22.9, 20.3+, 19.3+, 18.4+, 
7.6+, 5.6+, 5.3+
3/27 11 (2–29) 45 (26–65)
3.0 mg/kg 7/17 41 (18–67)‖ 22.4+, 18.3+, 15.2+, 12.9,  
11.1, 9.3, 9.2+
1/17 6 (0.1–29) 55 (30–80)
10.0 mg/kg 4/20 20 (6–44) 24.6+, 23.9+, 18.0+, 17.0 0/20 0 30 (9–51)
All doses 26/94 28 (19–38) 6/94 6 (2–13) 41 (30–51)
Non–small-cell lung cancer
Squamous
1.0 mg/kg 0/5 0 0/5 0 0
3.0 mg/kg 3/6 50 (12–88) ND 0/6 0 50 (10–90)
10.0 mg/kg 3/7 43 (10–82) ND 0/7 0 43 (6–80)
All doses 6/18 33 (13–59) ND 0/18 0 33 (12–55)
Nonsquamous
1.0 mg/kg 0/12 0 1/12 8 (0.2–39) 14 (0–37)
3.0 mg/kg 3/13 23 (5–54) ND 2/13 15 (2–45) 37 (10–64)
10.0 mg/kg 4/31 13 (4–30) ND 2/31 6 (0.8–21) 21 (6–36)
All doses 7/56 12 (5–24) ND 5/56 9 (3–20) 22 (11–34)
Unknown type
1.0 mg/kg 1/1 NA ND 0/1 0 NA
10.0 mg/kg 0/1 0 0/1 0 0
All types
1.0 mg/kg 1/18 6 (0.1–27) 9.2+ 1/18 6 (0.1–27) 16 (0–34)
3.0 mg/kg 6/19 32 (13–57) 30.8+, 7.6+, 5.5+, 3.7+, 1.9+, 
NA**
2/19 11 (1–33) 41 (18–64)
10.0 mg/kg 7/39 18 (8–34) 14.8+, 7.6+, 7.3+, 6.7, 4.2,  
3.7+, 3.7
2/39 5 (0.6–17) 24 (11–38)
All doses 14/76 18 (11–29) 5/76 7 (2–15) 26 (16–36)
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the possibility that any neoplasm could be im-
munogenic with proper immune activation; how-
ever, the reason why only a minority of patients 
had a response (i.e., tumor or patient [host] fac-
tors or both) is not known. The full therapeutic 
potential of PD-1 blockade across other tumor 
types remains to be defined.
The durability of objective responses across 
multiple cancer types in patients treated with 
anti–PD-1 antibody was also notable. Although 
anti–PD-1 antibody was not compared with other 
therapies in this study, this durability contrasts 
with the relatively modest durability of objective 
responses observed in many patients with non–
small-cell lung cancer, melanoma, or renal-cell 
cancer who are treated with conventional chemo-
therapy, tyrosine kinase inhibitors, or both. The 
response durability in heavily pretreated patients 
with lung cancer who received anti–PD-1 antibody 
is particularly interesting, because standard sal-
vage therapies historically have shown modest 
benefit in these patients.24 As measured by stan-
dard RECIST criteria in this study, objective re-
sponses were long-lasting, with response durations 
of 1 year or more in 20 of 31 patients who had a 
response with 1 year or more of follow-up. In ad-
dition, patterns of tumor regression consistent 
with immune-related patterns of response15,21,25 
were observed. That is, index lesions often re-
sponded as previously undetected lesions became 
detectable, a finding that is possibly related to 
lymphocyte infiltration of previously unknown 
small nests of tumor cells. Although the full ef-
fect of these unconventional response patterns 
remains to be defined in randomized trials with 
survival end points, these observations are rem-
iniscent of findings with ipilimumab in which a 
significant extension of overall survival was ob-
served in treated patients.7,8
Drug-related grade 3 or 4 toxic effects occurred 
in 14% of patients who received anti–PD-1 anti-
body, suggesting that therapy can be delivered in 
an outpatient setting with minimal supportive 
care. Among adverse events of special interest, 
pneumonitis was observed, with findings ranging 
from isolated radiographic abnormalities to pro-
gressive, diffuse infiltrates associated with clinical 
symptoms in a small number of patients. Although 
three deaths occurred, mild-to-moderate pneu-
monitis was managed successfully with either 
observation or glucocorticoids.
A particular challenge in cancer immuno-
Table 2. (Continued.) 






Rate‡ Duration of Response§ Stable Disease ≥24 wk
Progression-free 
Survival Rate  
at 24 wk¶
no. of patients/ 
total no. of 
patients % (95% CI) mo
no. of patients/ 
total no. of  
patients % (95% CI) % (95% CI)
Renal-cell cancer
1.0 mg/kg 4/17 24 (7–50) 17.5+, 9.2+, 9.2, 5.6+ 4/17 24 (7–50) 47 (23–71)
10.0 mg/kg 5/16 31 (11–59)‖ 22.3+, 21.7+, 12.9, 12.0, 8.4 5/16 31 (11–59) 67 (43–91)
All doses 9/33 27 (13–46) 9/33 27 (13–46) 56 (39–73)
*  The efficacy population consisted of patients in whom the response could be evaluated, whose treatment was initiated by July 1, 2011, and 
who had measurable disease at baseline with one of the following: at least one scan obtained during treatment, clinical evidence of disease 
progression, or death. NA denotes not applicable, and ND not determined.
†  Responses were adjudicated according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0, with modification (see 
Methods S1 in the Supplementary Appendix and the protocol).
‡  Objective response rate = [(complete responses + partial responses) ÷ total no. of patients] × 100. Rates were calculated on the basis of con-
firmed responses, with confidence intervals calculated with the use of the Clopper–Pearson method.
§  Duration of response was defined as the time from the first response to the time of documented progression, death, or, for censored data 
(denoted by a plus sign), the most recent tumor assessment.
¶  The progression-free survival rate is the proportion of patients without disease progression who were alive at 24 weeks; the rate was calcu-
lated according to the Kaplan–Meier method, with confidence intervals calculated with the use of the Greenwood method.
‖  Two patients (one with melanoma who received 3.0 mg of anti–PD-1 antibody per kilogram and one with renal-cell cancer who received 
10.0 mg per kilogram) had a complete response.
** One patient continued to receive treatment after an initial detection of progressive disease in preexisting lesions and subsequently had a 
partial response; this patient was classified as having had a response for the purpose of calculating response rates according to RECIST, 
version 1.0, but was not included in the calculation of duration of response.
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therapy has been the identification of mechanism-
based predictive biomarkers that could be used to 
identify candidates for such treatment and guide 
disease-management decisions. Our findings sug-
gest that PD-L1 expression in tumors is a candidate 
molecular marker that warrants further explora-
tion for use in selecting patients for immuno-
therapy with anti–PD-1 antibody. Our observa-
tion of an objective response in 36% of the 
patients with PD-L1–positive tumors and in none 
of those with PD-L1–negative tumors suggests 
that PD-L1 expression on the surface of tumor 
cells in pretreatment tumor specimens may be 
associated with an objective response. Although 
tumor-cell expression of PD-L1 may be driven by 
constitutive oncogenic pathways, recent research 
suggests that it may also reflect adaptive im-
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antitumor immune response, which may remain 
in check unless it is unleashed through blockade 
of the PD-1–PD-L1 pathway.19 Although our data 
on PD-L1 expression are consistent with current 
knowledge of the role of PD-L1 in tumor im-
mune resistance, additional studies will be need-
ed to define the role of PD-L1 as a potential 
predictive marker of response to anti–PD-1 anti-
body therapy.
This study and a companion study of anti–PD-
L1 antibody, now reported in the Journal,26 de-
scribe clinical activity with these agents that vali-
dates the importance of the PD-1–PD-L1 pathway 
for the treatment of some cancers. The signals 
of clinical activity in patients with non–small-
cell lung cancer, melanoma, and renal-cell can-
cer treated with anti–PD-1 antibody and the 
possibility of basing patient selection for such 
treatment on PD-L1 expression in tumors need to 
be prospectively assessed. Phase 2 trials involv-
ing immunologic and molecular-marker corre-
lates (ClinicalTrials.gov numbers, NCT01354431 
and NCT01358721) are under way, and phase 3 
studies of anti–PD-1 antibody for the treatment 
of non–small-cell lung cancer, melanoma, and 
renal-cell cancer are being planned. An assess-
ment of such treatment for other tumor types is 
also of interest.
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Figure 2 (facing page). Pharmacodynamic and Molecular-
Marker Assessments.
Panel A shows PD-1–receptor occupancy by anti–PD-1 
antibody. The graph at the left shows PD-1–receptor 
occupancy on circulating T cells in 65 patients with 
melanoma after one cycle (8 weeks) of treatment at  
a dose of 0.1 to 10.0 mg per kilogram every 2 weeks. 
Bars indicate median values. The graphs at the right 
show PD-1–receptor occupancy on CD3-gated peripheral-
blood mononuclear cells from a patient with melanoma 
who received 0.1 mg per kilogram, before treatment 
(top) and after one treatment cycle (bottom). Cells 
were stained with biotinylated antihuman IgG4 to de-
tect infused anti–PD-1 antibody bound to PD-1 mole-
cules on the cell surface. Detection was accomplished 
with the use of streptavidin–phycoerythrin, followed by 
flow-cytometric analysis. Dashed lines indicate isotype 
staining controls, and solid lines antihuman IgG4. Panel B 
shows the correlation of pretreatment tumor cell-surface 
expression of PD-1 ligand (PD-L1), as determined with 
immunohistochemical analysis of formalin-fixed, paraffin-
embedded specimens, with an objective response to 
PD-1 blockade in 42 patients with advanced cancers:  
18 with melanoma, 10 with non–small-cell lung cancer, 
7 with colorectal cancer, 5 with renal-cell cancer, and  
2 with castration-resistant prostate cancer. Tumor cell-
surface expression of PD-L1 was significantly correlated 
with an objective clinical response (graph at the left). 
No patients with PD-L1–negative tumors had an objec-
tive response. Of the 25 patients with PD-L1–positive 
tumors, 2 who were categorized as not having had a 
response at the time of data analysis are still under 
evaluation. Shown at the right are immunohistochemi-
cal analysis with the anti–PD-L1 monoclonal antibody 
5H1 in a specimen of a lymph-node metastasis from a 
patient with melanoma (top), a nephrectomy specimen 
from a patient with renal-cell cancer (RCC) (middle), 
and a specimen of a brain metastasis from a patient 
with lung adenocarcinoma (bottom). The arrow in each 
specimen indicates one of many tumor cells with surface-
membrane staining for PD-L1. The asterisk indicates  
a normal glomerulus in the nephrectomy specimen, 
which was negative for PD-L1 staining.
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